Publications by authors named "K Riecken"

The commonly altered glycosylation of tumor cells is a hallmark of tumor progression and metastasis formation. One prominent example is the interaction of sialylated glycans at the tumor cell surface with endothelial (E)-selectin as an early event of an adhesion cascade that enables extravasation of circulating tumor cells (CTCs) into distant tissues. In a previous study, we identified GCNT3 (mucin-type core2/ core4 β1,6-N-acetylglucosaminyltransferase) highly over-expressed in gastrointestinal adenocarcinoma cells that facilitate the canonical E-selectin ligands sialyl-Lewis A and X (sLeA/X) for E-selectin binding and endothelial adhesion.

View Article and Find Full Text PDF
Article Synopsis
  • There are significant differences in how various cancer types respond to systemic therapies, with leukemias and lymphomas responding better than solid tumors to treatments like chemotherapy.
  • Researchers engineered human cancer cell lines to express a modified herpes simplex virus gene that could potentially make all cell lines more uniformly susceptible to a drug called ganciclovir (GCV).
  • The study found that GCV was more effective on leukemia and lymphoma cells than on solid cancer cells, revealing that the origin of the tumor cells plays a critical role in their sensitivity to treatment.
View Article and Find Full Text PDF

Pro-inflammatory CD4 T cells are major drivers of autoimmune diseases, yet therapies modulating T cell phenotypes to promote an anti-inflammatory state are lacking. Here, we identify T helper 17 (T17) cell plasticity in the kidneys of patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis on the basis of single-cell (sc) T cell receptor analysis and scRNA velocity. To uncover molecules driving T cell polarization and plasticity, we established an in vivo pooled scCRISPR droplet sequencing (iCROP-seq) screen and applied it to mouse models of glomerulonephritis and colitis.

View Article and Find Full Text PDF

Due to their exceptional solubility and stability, nanobodies have emerged as powerful building blocks for research tools and therapeutics. However, their generation in llamas is cumbersome and costly. Here, by inserting an engineered llama immunoglobulin heavy chain (IgH) locus into IgH-deficient mice, we generate a transgenic mouse line, which we refer to as 'LamaMouse'.

View Article and Find Full Text PDF